Diabetic Retinopathy Should Not Be a Contraindication to Thrombolytic Therapy for Acute Myocardial Infarction: Review of Ocular Hemorrhage Incidence and Location in the GUSTO-I Trial fn1fn1This study was supported by Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genentech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.
Authors:
- Kenneth W. MahaffeyKMKenneth W. Mahaffey
- Christopher B. GrangerCGChristopher B. Granger
- Cynthia A. TothCTCynthia A. Toth
- Harvey D. WhiteHWHarvey D. White
- Amanda L. StebbinsASAmanda L. Stebbins
- Gabriel I. BarbashGBGabriel I. Barbash
- Alec VahanianAVAlec Vahanian
- Eric J. TopolETEric J. Topol
- Robert M. CaliffRCRobert M. Califf
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- ACC/AHA guidelines for the management of patients with acute myocardial infarctionJACC, 1996
- Mersey has changed its policyBMJ, 1995
- Thrombolysis in patients with diabetesBMJ, 1995
- Acute Myocardial Infarction in Diabetic Patients in the Thrombolytic EraDiabetic Medicine, 1994
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agentsJACC, 1993
- Intraocular Hemorrhage Associated with Intravenously Administered StreptokinaseAmerican Journal of Ophthalmology, 1991
- Retinal haemorrhage after thrombolytic therapyThe Lancet, 1991
- Guidelines for the early management of patients with acute myocardial infarctionJACC, 1990
- If Nothing Goes Wrong, Is Everything All Right?JAMA, 1983